KZR RSI Chart
Last 7 days
-1.3%
Last 30 days
-7.3%
Last 90 days
-9.5%
Trailing 12 Months
-71.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 0 | 0 | 7.0M |
2022 | 0 | 0 | 0 | 0 |
2021 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Aug 15, 2023 | morningside venture investments ltd | gifted | - | - | -3,500,000 | - |
Jul 20, 2023 | kirk christopher j. | acquired | 44,055 | 0.9 | 48,950 | - |
Feb 06, 2023 | morningside venture investments ltd | sold | -275,320 | 6.883 | -40,000 | - |
Feb 03, 2023 | morningside venture investments ltd | sold | -178,650 | 7.146 | -25,000 | - |
Feb 02, 2023 | morningside venture investments ltd | sold | -359,500 | 7.19 | -50,000 | - |
Feb 01, 2023 | morningside venture investments ltd | sold | -278,000 | 6.95 | -40,000 | - |
Jan 31, 2023 | morningside venture investments ltd | sold | -212,400 | 7.08 | -30,000 | - |
Jan 30, 2023 | morningside venture investments ltd | sold | -207,300 | 6.91 | -30,000 | - |
Jan 25, 2023 | morningside venture investments ltd | sold | -342,500 | 6.85 | -50,000 | - |
Jan 24, 2023 | morningside venture investments ltd | sold | -558,400 | 6.98 | -80,000 | - |
Which funds bought or sold KZR recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Ikarian Capital, LLC | added | 1.83 | -25,019 | 783,484 | 0.09% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | sold off | -100 | -11,129 | - | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -64.61 | -43,629 | 22,151 | -% |
May 15, 2024 | Prosight Management, LP | reduced | -71.37 | -2,319,540 | 868,780 | 0.24% |
May 15, 2024 | ORBIMED ADVISORS LLC | unchanged | - | -88,257 | 1,737,380 | 0.03% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | reduced | -31.53 | -52,344 | 97,914 | -% |
May 15, 2024 | IRONWOOD INVESTMENT MANAGEMENT LLC | added | 11.39 | 1,431 | 25,256 | 0.01% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | added | 7.07 | 21,840 | 1,174,110 | -% |
May 15, 2024 | TANG CAPITAL MANAGEMENT LLC | added | 124 | 330,617 | 621,151 | 0.06% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -72.09 | -2,036,990 | 736,583 | -% |
Unveiling Kezar Life Sciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Kezar Life Sciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Kezar Life Sciences Inc News
Income Statement (Quarterly) | |||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2021Q4 |
Revenue | -100.0% | - | 7,000 | - | - | - | - |
Operating Expenses | 6.3% | 34,589 | 32,527 | 26,784 | 24,524 | 20,034 | 14,103 |
S&GA Expenses | -34.5% | 5,760 | 8,789 | 5,785 | 6,206 | 5,175 | 4,322 |
R&D Expenses | -4.6% | 22,642 | 23,738 | 20,999 | 18,318 | 14,859 | 9,781 |
Interest Expenses | 0.8% | 399 | 396 | 385 | 370 | 349 | 159 |
Net Income | -39.6% | -32,260 | -23,103 | -24,308 | -22,199 | -18,181 | -14,212 |
Net Income Margin | -Infinity% | -14.55* | - | - | - | - | - |
Free Cashflow | 6.7% | -18,981 | -20,341 | -22,976 | -21,157 | -16,226 | -11,347 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -10.0% | 199 | 221 | 249 | 263 | 284 | 300 | 305 | 318 | 252 | 218 | 131 | 140 | 152 | 152 | 161 | 168 | 135 | 90.00 | 98.00 | 105 | 113 |
Current Assets | -10.3% | 186 | 207 | 231 | 244 | 265 | 286 | 299 | 311 | 246 | 212 | 125 | 133 | 146 | 145 | 154 | 161 | 127 | 81.00 | 89.00 | 96.00 | 104 |
Cash Equivalents | -6.9% | 33.00 | 35.00 | 26.00 | 28.00 | 36.00 | 40.00 | 64.00 | 105 | 39.00 | 63.00 | 57.00 | 26.00 | 23.00 | 21.00 | 13.00 | 17.00 | 21.00 | 15.00 | 20.00 | 13.00 | 18.00 |
Net PPE | -6.6% | 4.00 | 4.00 | 4.00 | 5.00 | 5.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 |
Liabilities | -10.9% | 30.00 | 34.00 | 33.00 | 31.00 | 32.00 | 30.00 | 22.00 | 20.00 | 20.00 | 21.00 | 11.00 | 10.00 | 12.00 | 11.00 | 11.00 | 10.00 | 12.00 | 11.00 | 11.00 | 11.00 | 11.00 |
Current Liabilities | -8.9% | 16.00 | 18.00 | 17.00 | 14.00 | 14.00 | 11.00 | 10.00 | 8.00 | 7.00 | 8.00 | 8.00 | 6.00 | 8.00 | 6.00 | 6.00 | 5.00 | 7.00 | 6.00 | 5.00 | 5.00 | 5.00 |
Long Term Debt | -12.3% | 9.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -9.8% | 169 | 188 | 216 | 232 | 252 | 270 | 283 | 297 | 232 | 197 | 119 | 130 | 141 | 141 | 150 | 158 | 123 | 78.00 | 86.00 | 95.00 | 102 |
Retained Earnings | -6.2% | -372 | -350 | -318 | -295 | -271 | -248 | -230 | -212 | -196 | -180 | -166 | -151 | -139 | -126 | -115 | -103 | -94.30 | -84.28 | -74.70 | -65.56 | -56.84 |
Additional Paid-In Capital | 0.6% | 542 | 538 | 535 | 528 | 524 | 520 | 515 | 511 | 430 | 378 | 286 | 282 | 280 | 267 | 265 | 262 | 217 | 163 | 161 | 160 | 159 |
Shares Outstanding | 0.0% | 73.00 | 73.00 | 73.00 | 73.00 | 71.00 | 68.00 | 72.00 | 64.00 | 61.00 | 53.00 | 52.00 | 51.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 173 | - | - | - | 551 | - | - | - | 252 | - | - | - | 174 | - | - | - | 119 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -20.5% | -22,862 | -18,980 | -20,205 | -21,600 | -20,860 | -15,883 | -16,360 | -13,289 | -13,314 | -11,081 | -9,954 | -13,045 | -8,357 | -9,307 | -9,250 | -10,091 | -8,301 | -7,210 | -8,255 | -7,712 | -6,700 |
Share Based Compensation | 6.6% | 3,434 | 3,220 | 6,634 | 4,020 | 4,263 | 3,817 | 3,787 | 3,298 | 3,104 | 1,853 | 1,878 | 1,937 | 1,928 | 1,280 | 1,271 | 1,219 | 1,173 | 1,007 | 1,090 | 1,009 | 901 |
Cashflow From Investing | -26.8% | 20,408 | 27,878 | 18,574 | 13,203 | 16,391 | -8,661 | -24,708 | 1,510 | -59,533 | -82,491 | 38,484 | 16,250 | -687 | 17,318 | 2,790 | -37,276 | -39,330 | 1,678 | 15,623 | 2,142 | 976 |
Cashflow From Financing | -100.0% | - | 59.00 | 43.00 | 382 | 154 | 506 | 185 | 78,322 | 48,848 | 99,356 | 2,212 | 282 | 10,735 | 317 | 1,962 | 43,995 | 53,368 | 80.00 | 8.00 | 180 | 4.00 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 17,172 | $ 18,318 |
General and administrative | 6,539 | 6,206 |
Total operating expenses | 23,711 | 24,524 |
Loss from operations | (23,711) | (24,524) |
Interest income | 2,453 | 2,695 |
Interest expense | (400) | (370) |
Net loss | $ (21,658) | $ (22,199) |
Net loss per common share, Basic | $ (0.3) | $ (0.31) |
Net loss per common share, Diluted | $ (0.3) | $ (0.31) |
Weighted-average shares used to compute net loss per common share, Basic | 72,799,910 | 72,328,231 |
Weighted-average shares used to compute net loss per common share, Diluted | 72,799,910 | 72,328,231 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 33,032 | $ 35,493 |
Marketable securities | 146,766 | 165,879 |
Prepaid expenses and other current assets | 5,815 | 5,578 |
Total current assets | 185,613 | 206,950 |
Property and equipment, net | 3,652 | 3,912 |
Operating lease right-of-use asset | 4,364 | 4,778 |
Other assets | 5,501 | 5,595 |
Total assets | 199,130 | 221,235 |
Current liabilities: | ||
Accounts payable | 5,059 | 8,251 |
Accrued and other current liabilities | 6,664 | 6,481 |
Operating lease liabilities, current | 3,134 | 3,012 |
Debt, current | 1,304 | 0 |
Total current liabilities | 16,161 | 17,744 |
Operating lease liabilities, noncurrent | 5,019 | 5,852 |
Debt, noncurrent | 8,829 | 10,069 |
Total liabilities | 30,009 | 33,665 |
Stockholders' equity: | ||
Common stock, $0.001 par value, 250,000,000 and 250,000,000 shares authorized as of March 31, 2024 (unaudited) and December 31, 2023, respectively; 72,801,359 and 72,779,077 shares issued and outstanding as of March 31, 2024 (unaudited) and December 31, 2023, respectively | 73 | 73 |
Preferred stock, $0.001 par value, 10,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2024 (unaudited) and December 31, 2023 | 0 | 0 |
Additional paid-in capital | 541,824 | 538,390 |
Accumulated other comprehensive loss | (355) | (130) |
Accumulated deficit | (372,421) | (350,763) |
Total stockholders' equity | 169,121 | 187,570 |
Total liabilities and stockholders' equity | $ 199,130 | $ 221,235 |